Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEACOPP escalated + baseline vs ABVD in advanced Hodgkin lymphoma (stage III-IV)
2004-001558-10Phase 3Completed
- Sponsor
- Hospital de la Santa Creu i Sant Pau
- Start
- Sep 2004
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine and 4 more in Hodgkin lymphoma (HL) (2 arms), sponsored by Hospital de la Santa Creu i Sant Pau. Primary endpoints: Time to treatment failure, Complete remission rate and 5 more. Started Sep 2004; status: completed.
02
Drugs
bleomycinetoposidedoxorubicincyclophosphamidevincristine
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2004-001558-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001558-10.